Program: Oral and Poster Abstracts
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster I
Methods: A retrospective cohort study of Medicare patients with MM receiving second-line (2L) anti-MM TXs was conducted. Patients were selected from the Truven MarketScan© administrative claims database Medicare Supplemental files who had ≥2 outpatient claims or ≥1 inpatient claim with a primary International Classification of Disease 9th Revision (ICD-9) code for MM between 7/1/2006 and 12/31/2013, preceded by ≥ 6 months without a claim for MM. Patients were then followed until last visit or 12/31/2014, whichever occurred first. First line (1L) therapy included all anti-MM TXs received following the first claim for an anti-MM prescription/administration. The end of line of therapy was defined as the first day of any gap in TX > 90 days or initiation of a new salvage regimen. Patients who received 2L TX were further divided into two 2 cohorts. Cohort 1 included patients with a minimum 6-months treatment-free interval (TFI) after completing 2L TX. Patients whose disease progressed within 6 months from completion of 2L TX, as identified by the initiation of third-line (3L) TX, comprised Cohort 2. A phase-of-care approach was adopted to calculate the cost of DP. Total all-cause, medical, and anti-MM pharmacological spending were calculated using a standard cost per-patient per-month (PPPM) metric in the 6-month TFI in Cohort 1 and in the 6 months following initiation of 3L TX in Cohort 2. Unadjusted costs were compared between the two cohorts using the Mann-Whitney U- test. A multivariate regression analysis was used to adjust for baseline characteristics that may confound the observed association between DP status and cost of care.
Results: A total of 986 Medicare beneficiaries met the study eligibility criteria and initiated 2L therapy in the study period and 650 had at least 6 months of cost data. Of these, 354 patients were in Cohort 1 and 296 patients were in cohort 2. Average PPPM total all-cause and all-cause medical costs were $7,031 and $4,607, respectively, with costs for patients in Cohort 2 significantly higher than costs in Cohort 1. The average PPPM total all-cause and all-cause medical costs were $2,302 and $2,041, respectively, for patients in Cohort 1 (Table 1). In the multivariate regression model, DP was the strongest predictor of total all-cause costs and was associated with an increase of $4,721 (p<0.0001) in PPPM total all-cause costs (Table 2). All-cause medical costs were $2,560 (p<.0001) higher in Cohort 2 compared with Cohort 1, suggesting that the increased costs associated with DP were not entirely attributable to anti-MM TX costs.
Table 1. 6-month mean cost PPPM overall and by category
|
DP in 6 months from the completion of 2L treatment |
CP-CNP |
CP/CNP |
p-Value† |
|
|
No (n=354) |
Yes (n=296) |
|
|
|
Total all-cause cost |
$2,302 |
$7,031 |
$4,729 |
3.0 |
0.0000 |
Anti-MM therapy |
$0 |
$2,685 |
$2,685 |
- |
- |
Medical cost‡ |
$2,041 |
$4,607 |
$2,566 |
2.3 |
0.0000 |
CP, cost of progression; CNP, cost of not progressing. The all-cause inpatient/outpatient and anti-MM therapy cost categories both include fees for physician administered (injected) drugs. All figures inflated to 2015$.
† Mann-Whitney U-test
‡ Medical cost includes inpatient/outpatient, lab, procedure, and all other costs.
Table 2. Multivariate regression analysis of mean PPPM cost†
|
Coefficient |
95% CI |
p-value |
Disease progression |
$4,721 |
$3,918–$5,525 |
0.000 |
No progression |
Ref |
|
Notes: Ref = reference group.
†The model was adjusted for age, region, and gender.
Conclusions: Results of this study may help quantify the economic benefits of delaying progression of MM in the real-world setting. This study indicates therapies that delay progression and extend treatment free intervals for patients with first-relapsed MM may result in cost savings, potentially offsetting the cost of therapies that have been demonstrated to yield significant clinical benefits in terms of delayed progression.
Disclosures: MacEwan: Precision Health Economics: Employment ; Bristol-Myers Squibb: Consultancy . Batt: Bristol-Myers Squibb: Consultancy . Yin: Bristol-Myers Squibb: Consultancy . Peneva: Precision Health Economics: Employment ; Bristol-Myers Squibb: Consultancy . Sison: Precision Health Economics: Employment ; Bristol-Myers Squibb: Consultancy . Vine: Precision Health Economics: Employment ; Bristol-Myers Squibb: Consultancy . Shah: Bristol-Myers Squibb: Employment , Other: Stocks . Chen: Bristol-Myers Squibb: Employment .
See more of: Health Services and Outcomes Research – Malignant Diseases
See more of: Oral and Poster Abstracts
*signifies non-member of ASH